KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.

Silva Arslanian, Inge Gies, Bryan Goldman, Tobias Karlsson, Aaron S Kelly, Mette Skalshøi Kjær, Antje Körner, Mazen Noureddin, Martin Wabitsch, Nina M Harder-Lauridsen, Daniel Weghuber

Diabetes Care 49(6) 954-962

PMID41296499
PMCIDPMC13191423
DOI10.2337/dc25-0824
发表日期2025-11-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:非 KM 图。
摘要

摘要

OBJECTIVE: This secondary analysis of the Semaglutide Treatment Effect in People with obesity (STEP) TEENS (NCT04102189) study investigated the effect of semaglutide 2.4 mg versus placebo on insulin sensitivity and cardiometabolic risk factors. RESEARCH DESIGN AND METHODS: The STEP TEENS phase 3a randomized study in adolescents (aged 12 to <18 years) with obesity demonstrated that once-weekly subcutaneous semaglutide 2.4 mg provided a significantly greater percentage reduction in BMI than placebo at week 68 (estimated difference -16.7 percentage points; P = 0.0001). This analysis investigated changes in insulin sensitivity and cardiometabolic risk factors from baseline to week 68. RESULTS: Overall, 193 participants without type 2 diabetes were included in the analysis. Participants receiving semaglutide 2.4 mg (n = 129) compared with those receiving placebo (n = 64) had greater reductions from baseline in fasting serum insulin (-33.6% vs. -10.1%; P = 0.0012), homeostatic model assessment for insulin resistance (HOMA-IR) score (-35.0% vs. -5.3%; P = 0.0002), glycemic measures (glycated hemoglobin: P < 0.0001; fasting plasma glucose: P = 0.0181), alanine aminotransferase (ALT; -17.9% vs. -3.3%; P = 0.0232), waist-to-height ratio (P < 0.0001), triglycerides (P < 0.0001), LDL cholesterol (P = 0.0105), and total cholesterol (P < 0.0001). Moreover, greater improvements in insulin sensitivity, glycemic measures, and cardiometabolic risk factors were seen in semaglutide 2.4 mg recipients with BMI reductions of ≥20% versus <20%. CONCLUSIONS: These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1Mean changes from baseline in fasting serum insulin ( A ), HOMA-IR ( B ), fasting plasma glucose ( C ), HbA 1c ( D ), and ALT ( E ) for semaglutide 2.4 mg versus placebo. Observed mean change for participants in the full analysis set during the in-trial observation period over time (error bars indicate ±95% CI of the mean). ETDs are for the treatment policy estimand at week 68. Fasting serum insulin, HOMA-IR, and ALT were analyzed as ratio to baseline, with ETD in percentage change calculated as (estimated treatment ratio − 1) ∗ 100.
非 KM Figure
Figure 2Changes in cardiometabolic risk factors from baseline to week 68 for the semaglutide 2.4 mg versus placebo groups. Data are mean change from baseline unless otherwise stated. Observed data are for the in-trial observation period. ETDs are for the treatment policy estimand at week 68.
非 KM Figure
Figure 3Changes in glucose metabolism parameters and serum lipids from baseline to week 68 by BMI reduction in the semaglutide 2.4 mg group: HbA 1c ( A ), FPG ( B ), fasting serum insulin ( C ), HOMA-IR ( D ), triglycerides ( E ), total cholesterol ( F ), LDL cholesterol ( G ), VLDL cholesterol ( H ), and HDL cholesterol ( I ). Data are percentage change from baseline for participants in the full analysis set during the in-trial observation period.
非 KM Figure